cefuroxime has been researched along with Pneumonia, Pneumococcal in 19 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Pneumonia, Pneumococcal: A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical and microbiological efficacy, as well as the tolerability of the amoxicillin/sulbactam combination as empiric treatment for complicated community-acquired pneumonia (CCAP) were evaluated in children from 3 months to 15 years with CCAP who were randomized 1:1 to receive either amoxicillin/sulbactam or cefuroxime." | 9.11 | Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam. ( Arbo, A; Lovera, D, 2005) |
| "A regimen of cefprozil (500 mg twice daily), a new oral cephalosporin with a broad in vitro spectrum of antimicrobial activity, was compared to standard regimens of cefaclor (500 mg three times daily), cefuroxime axetil (500 mg twice daily), or amoxicillin/clavulanate (500 mg/125 mg three times daily) for the treatment of lower respiratory tract infections (mainly bronchitis and acute exacerbations of chronic bronchitis) in adults in three open-label, randomized trials." | 6.17 | Review of the experience with cefprozil for the treatment of lower respiratory tract infections. ( Pelletier, LL, 1992) |
| "Cefuroxime axetil is an oral cephalosporin with proven efficacy in adult lower respiratory tract infections." | 5.29 | [Treatment of bacterial pneumonias with cefuroxime-axetil. Predictive value of measurement of the in vitro susceptibility]. ( Cluzel, R; Modaï, J; Portier, H, 1996) |
| "The clinical and microbiological efficacy, as well as the tolerability of the amoxicillin/sulbactam combination as empiric treatment for complicated community-acquired pneumonia (CCAP) were evaluated in children from 3 months to 15 years with CCAP who were randomized 1:1 to receive either amoxicillin/sulbactam or cefuroxime." | 5.11 | Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam. ( Arbo, A; Lovera, D, 2005) |
| " We report a toddler who had breakthrough bacteremia and meningitis develop because of drug-resistant pneumococcus while receiving treatment with cefotaxime and cefuroxime for pneumonia." | 3.70 | Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. ( Brown, SP; Buckingham, SC; Joaquin, VH, 1998) |
| "The therapeutic activity of FCE 22891 was compared with that of two new oral cephalosporins, cefuroxime axetil and cefixime against Streptococcus pneumoniae respiratory infection and subcutaneous abscesses induced by mixed aerobes and anaerobes in mice." | 3.67 | Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice. ( Castellani, P; Della Bruna, C; Rossi, R; Younes, G, 1989) |
| "Levofloxacin is a new fluoroquinolone active against S." | 2.69 | [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. ( Léophonte, P; Veyssier, P, 1999) |
| "Cefuroxime was given by i." | 2.67 | Cefuroxime efficacy in pneumonia: sequential short-course i.v./oral suspension therapy. ( Cuningham, K; Dagan, R; Engelhard, D; Ephros, M; Shalit, I, 1994) |
| "Infants and children with pneumococcal infections cared for at eight children's hospitals." | 1.31 | Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. ( Barson, WJ; Bradley, JS; Givner, LB; Kaplan, SL; Kim, KS; Mason, EO; Schutze, GE; Tan, TQ; Wald, ER; Yogev, R, 2001) |
| "Cefuroxime axetil is an oral cephalosporin with proven efficacy in adult lower respiratory tract infections." | 1.29 | [Treatment of bacterial pneumonias with cefuroxime-axetil. Predictive value of measurement of the in vitro susceptibility]. ( Cluzel, R; Modaï, J; Portier, H, 1996) |
| "Vancomycin was the most effective in vivo as measured by the 50% effective dose (ED50) after single doses 1 h post-inoculation." | 1.27 | The pneumococcus and the mouse-protection test: correlation of in vitro and in vivo activity for beta-lactam antibiotics, vancomycin, erythromycin and gentamicin. ( Frimodt-Møller, N; Thomsen, VF, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 11 (57.89) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yayan, J | 1 |
| Ghebremedhin, B | 1 |
| Rasche, K | 1 |
| Wiener-Well, Y | 1 |
| Raveh, D | 1 |
| Schlesinger, Y | 1 |
| Yinnon, AM | 1 |
| Rudensky, B | 1 |
| Lode, H | 1 |
| File, TM | 1 |
| Mandell, L | 1 |
| Ball, P | 1 |
| Pypstra, R | 1 |
| Thomas, M | 1 |
| Lovera, D | 1 |
| Arbo, A | 1 |
| Shalit, I | 1 |
| Dagan, R | 1 |
| Engelhard, D | 1 |
| Ephros, M | 1 |
| Cuningham, K | 1 |
| Caballero-Granado, FJ | 1 |
| Palomino-Nicás, J | 1 |
| Pachón, J | 1 |
| García-Curiel, A | 1 |
| Cluzel, R | 1 |
| Portier, H | 1 |
| Modaï, J | 1 |
| Verhaegen, J | 1 |
| Vandeven, J | 1 |
| Verbiest, N | 1 |
| Fossion, M | 1 |
| Mengeot, PM | 1 |
| Amougou, M | 1 |
| Verbist, L | 1 |
| Buckingham, SC | 1 |
| Brown, SP | 1 |
| Joaquin, VH | 1 |
| Tan, TQ | 2 |
| Mason, EO | 2 |
| Barson, WJ | 2 |
| Wald, ER | 2 |
| Schutze, GE | 2 |
| Bradley, JS | 2 |
| Arditi, M | 1 |
| Givner, LB | 2 |
| Yogev, R | 2 |
| Kim, KS | 2 |
| Kaplan, SL | 2 |
| Dowell, SF | 1 |
| Smith, T | 1 |
| Leversedge, K | 1 |
| Snitzer, J | 1 |
| Léophonte, P | 1 |
| Veyssier, P | 1 |
| Calvo, A | 1 |
| Amores, R | 1 |
| Valero, E | 1 |
| Sevillano, D | 1 |
| Prieto, J | 1 |
| Singh, KP | 1 |
| Voolmann, T | 1 |
| Lang, SD | 1 |
| Pelletier, LL | 1 |
| Zamotaev, IP | 1 |
| Sokolova, VI | 1 |
| Kamnev, IuV | 1 |
| Bormotova, MS | 1 |
| Rossi, R | 1 |
| Castellani, P | 1 |
| Younes, G | 1 |
| Della Bruna, C | 1 |
| Frimodt-Møller, N | 1 |
| Thomsen, VF | 1 |
1 review available for cefuroxime and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Review of the experience with cefprozil for the treatment of lower respiratory tract infections.
Topics: Acute Disease; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Bronchopneumo | 1992 |
5 trials available for cefuroxime and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical effic
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infect | 2002 |
Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Cefuroxime; Child; Child, Preschool; Community-Acqui | 2005 |
Cefuroxime efficacy in pneumonia: sequential short-course i.v./oral suspension therapy.
Topics: Acute Disease; Administration, Oral; Cefuroxime; Child, Preschool; Community-Acquired Infections; Dr | 1994 |
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Clavulanic Acid; Community | 1999 |
Review of the experience with cefprozil for the treatment of lower respiratory tract infections.
Topics: Acute Disease; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Bronchopneumo | 1992 |
14 other studies available for cefuroxime and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
No Resistance to Penicillin, Cefuroxime, Cefotaxime, or Vancomycin in Pneumococcal Pneumonia.
Topics: Aged; Cefotaxime; Cefuroxime; Cephalosporin Resistance; Cross Infection; Drug Resistance, Bacterial; | 2015 |
Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cefuroxime; | 2009 |
Cefuroxime efficacy in treatment of bacteremic pneumonia due to penicillin-resistant and cefuroxime-resistant Streptococcus pneumoniae.
Topics: Adolescent; Aged; Cefuroxime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Male; Middle | 1996 |
[Treatment of bacterial pneumonias with cefuroxime-axetil. Predictive value of measurement of the in vitro susceptibility].
Topics: Adolescent; Adult; Aged; Cefuroxime; Cephalosporins; Female; Haemophilus influenzae; Humans; Male; M | 1996 |
Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Cephalosporin Resistance; C | 1997 |
Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.
Topics: Bacteremia; Cefotaxime; Cefuroxime; Cephalosporin Resistance; Cephalosporins; Drug Resistance, Multi | 1998 |
Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae.
Topics: Adolescent; Adult; Ambulatory Care; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Cephalosporins; | 1998 |
Failure of treatment of pneumonia associated with highly resistant pneumococci in a child.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefotaxime; Cefuroxime; Cephalosporins; Drug Therapy, | 1999 |
Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; Bacteremia; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporin Resistance; Ce | 2001 |
[Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefixime; Cefpodoxime; Ceftibuten; Cefti | 2001 |
Pneumococcal bacteraemia in south Auckland: a five year review with emphasis on prescribing practices.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacteremia; Cefuroxi | 1992 |
[A case of successful antibiotic therapy of legionnaires' disease with lesions of the lungs and heart].
Topics: Atrial Fibrillation; Cefuroxime; Cephalosporins; Digoxin; Drug Therapy, Combination; Female; Humans; | 1990 |
Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; Bacteroides Inf | 1989 |
The pneumococcus and the mouse-protection test: correlation of in vitro and in vivo activity for beta-lactam antibiotics, vancomycin, erythromycin and gentamicin.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Dose-Response Relationship, Drug; Erythromycin; Gentamic | 1987 |